From scientific vision to reality
The gap between discovery and delivery
Molecular assays and NGS have transformed our ability to investigate and understand genomics at a fundamental level, and their applications in healthcare continue to expand. From the diagnosis of rare genetic conditions to the development of new therapies and vaccines, the potential is vast. But translating that potential into robust, reliable, market-ready solutions is rarely straightforward.
Developing molecular assays and IVD products demands a rare combination of scientific creativity, technical rigour, and regulatory expertise. The technology landscape is crowded and fast-moving, the regulatory requirements are exacting, and the path from a promising concept to a validated, compliant product requires careful navigation at every stage.
I established IntelliGene Diagnostics to provide exactly that kind of support, working with organisations that have the scientific vision and need an experienced partner to help them execute it. Whether that means developing a new assay, establishing a specialist laboratory, managing a complex R&D programme, or providing senior scientific leadership, the goal is always the same - to help clients deliver innovative solutions that make a real difference to patients.
I am a molecular biologist and IVD specialist with a passion for scientific innovation and the transformative impact it can have on healthcare. My work spans molecular assay and IVD product development, NGS workflows, project management, and scientific leadership. I enjoy working across all levels, from testing ideas at the bench to providing senior leadership and strategic input.
I spent the first ten years of my career in academia researching genetics and genomics, including a PhD and PostDoc positions (Imperial College London, University of Nottingham, University of Leicester). I evaluated clinical research samples, explored emerging molecular technologies, and saw NGS emerge as a transformative force. It was always fascinating to be able to pinpoint, at a molecular level, the genetic basis of disease. I wanted to continue doing that, in a setting that could more directly benefit patients, and moved into molecular diagnostics.
I spent the next decade in biotech, mostly in diagnostics, always working with DNA (Oxford Nanopore, DNA Script, DNA Electronics, Enigma Diagnostics). I developed CE-IVD assays, gained deep insight into NGS platform development, and broadened my expertise into synthetic biology and automation. Most recently, I established and led the Diagnostic Applications team at Oxford Nanopore, a multidisciplinary group responsible for the development of novel diagnostic assays that harness the unique benefits of nanopore sequencing.
I now work independently through IntelliGene Diagnostics, collaborating with academic institutions, biotechs and biopharma companies on projects that span the full breadth of my expertise. I am driven by the potential to make a difference through rigorous science, creative problem solving, and a commitment to delivering work that has real impact.
